Commissariat a L'energie Atomique

Commissariat &#xc0; L'&#xc9;nergie Atomique Et Aux &#xc9;nergies Alternatives

Institut National De La Sante Et De La Recherche Medicale

Centre National De La Recherche Scientifique

Sedac Therapeutics

Proteus Gmbh

Universite De Lille II

Bernard Maillere

Thierry Livache

Daniel Gillet

Bertrand Georges

Jean-Gérard Guillet

Stéphane Depil

Patrice Marche

Alain Sanson

Helene Nuyttens

Hélène Nuyttens

Isabelle Bourgault-Villada

Yoann Roupioz

Olivier Morales

XiaoFei Wang

Gaetan Munier

Claire Chevaleyre

Sandra Moratille

Florence Castelli-Golfier

Véronique Pancre

Florence Castelli

Sarah Milgram

Cécile Buhot

Emmanuel Favry

Sandra Pouvelle-Moratille

Benoit Villiers

Sandra Pouvelle

Catherine Texier

Sylvain Pichard

Andr&eacute; Menez

Anaïs M'Houmadi

Xiaofei Wang

Gaétan Munier

Claude 55 Avenue De Cannes Auriault

Anaïs Mouhmadi

Stéphanie Delluc-Desroches

The present invention relates to peptides comprising at least one CD4T epitope, which is immunodominant in vitro, of the cyclin B1 tumor antigen, said peptides being capable of stimulating a specific human CD4T lymphocyte response in subjects who have varied HLA II molecules, and to the use of these peptides as a cancer vaccine and as a reagent for the diagnosis of cancer or the immunomonitoring of the cellular response against cyclin B1 during cancer or during an anticancer treatment.

Immunogenic peptides of the cyclin B1 tumor antigen

The present invention relates to a method for real-time measurement of the secretion of at least one compound by at least one individual cell, comprising:

Method for real-time measurement of the individual secretions of a cell

A ligand recombinant protein inhibiting HB-EGF (Heparin-Binding Epidermal Growth Factor like), from the R domain of diphtheria toxin, which can be used for the treatment and diagnosis of diseases involving the activation of the HB-EGF/EGFR pathway.

HB-EGF inhibitor derived from the R domain of diphtheria toxin for the treatment of diseases associated with the activation of the HB-EGF/EGFR pathway

The present invention concerns CD4+ T survivin epitopes and their vaccines and diagnostic uses.

CD4+ T survivin epitopes and uses thereof

A method of selecting a test molecule that binds to HLA-DP4 by (i) incubating HLA-DP4 with the test molecule and a labeled peptide of formula (I) ZXXXXXXXXXZthereby forming respective complexes, wherein Zand Z, which may be identical or different, are each either zero or from 1 to 100 amino acids; Xis an aromatic or hydrophobic amino acid, or S; Xis an aromatic or hydrophobic amino acid, or C; Xis an aromatic or hydrophobic amino acid, or C, D, Q, S, T, or E; and X, X, X, X, Xand Xare each an amino acid; (ii) separating the respective complexes formed; (iii) detecting the HLA-DP4/labeled peptide complexes; and (iv) selecting the test molecule that exhibits a binding activity of IC&#x3c;1000 nM, which corresponds to the concentration of the test molecule that inhibits 50% of the competitive HLA-DP4 binding of the labeled peptide.

Method of selecting HLA-DP4 ligands and the applications thereof

The invention concerns a mixture of peptides derived from the E6 and/or E7 proteins of a papillomavirus involved in cervix of uterus cancer, such as HPV16, HPV18, HPV30, HPV31, HPV32, HPV33, HPV34, HPV35, HPV39, HPV40, HPV42, HPV43, HPV44, HPV45, HPV51, HPV52, HPV56, HPV57, and HPV58, for example, as well as its uses as medicine (in immunogenic compositions, capable of stimulating the production of anti-HPV T CD4+ lymphocytes in vivo and hence useful for vaccination against uterine of uterus cancer and in other cancers) or as diagnostic reagent of HPV-specific T lymphocytes, in particular for assessing the immune condition of patients. The invention also concerns a mixture of peptides derived from E6 and/or E7 proteins of a papillomavirus involved in benign skin lesions (for example warts), such as HPV10, HPV3 or HPV4 and its uses as medicine.

Mixture of peptides derived from E6 and/or E7 papillomavirus proteins and uses thereof

The invention concerns peptides and proteins for desensitizing specifically the vast majority of subjects allergic to bee venom and compositions containing said peptides or proteins. The peptides are selected in the group consisting of: the fragment (1) corresponding to positions P85-97 of the major bee venom allergen, the fragment (2) corresponding to positions P81-93 of the major bee venom allergen, the fragment (3) corresponding to positions P94-106 of the major bee venom allergen, the fragment (4) corresponding to positions P76-88 of the major bee venom allergen, the fragment (5) corresponding to positions P77-94 of the major bee venom allergen, and the fragment (6) corresponding to positions P122-134 of the major bee venom allergen, fragments (I) and (2) forming group (1); fragment (3) forming group (II); fragments (4) and (4) forming group (III) and fragment (6) forming group IV and the mutated fragments of said fragments (1) to (6) which have a binding activity with MHC class (II) molecules identical or higher than those of said fragments (1) to (6). The invention also concerns compositions containing said peptides or proteins.

Peptides and proteins for desensitizing subjects allergic to bee venom and compositions containing same

Growing community of inventors

Versailles, France

Bernard Maillere